The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso

Journal of the International AIDS Society

Volumn 17, Issue , 2014, Pages

  Penot, Pauline ^a,b   Héma, Arsène ^a   Bado, Guillaume ^a   Kaboré, Firmin ^a   Soré, Ibrahim ^a   Sombié, Diamasso ^a   Traoré, Jean Richard ^a   Guiard Schmid, Jean Baptiste ^c   Fontanet, Arnaud ^d,e   Slama, Laurence ^f   Sawadogo, Adrien Bruno ^a   Laurent, Christian ^b  

^a Hôpital de Jour du Service de Médecine Interne du CHU Sanou Souro   (Burkina Faso)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c Initiatives Conseil International Santé ICI santé   (Burkina Faso)

^d INSTITUT PASTEUR   (France)

^e University of Paris Cité   (France)

^f HÔPITAL TENON   (France)

Author keywords

Africa; Antiretroviral; Efficacy; Gender; HIV; Virologic failure

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BURKINA FASO; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT DURATION; VIROLOGIC FAILURE;

AFRICA; ANTIRETROVIRAL; EFFICACY; GENDER; HIV; VIROLOGIC FAILURE;

ADULT; ANTI-HIV AGENTS; BURKINA FASO; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; MIDDLE AGED; SEX FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 84896886070     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.17.1.18646     Document Type: Article

References (38)

1. Cornell M, McIntyre J, Myer L. Men and antiretroviral therapy in Africa: our blind spot. Trop Med Int Health. 2011;16(7):828-9.
2. WHO, UNICEF, UNAIDS. Global update on HIV treatment 2013: results, impact and opportunities. 2013 [cited 2013 Aug 19]. Available from: http://apps.who.int/iris/bitstream/10665/85326/1/9789241505734-eng.pdf
3. Braitstein P, Boulle A, Nash D, Brinkhof MW, Dabis F, Laurent C, et al. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health. 2008;17(1):47-55. (Pubitemid 351197536)
4. Kigozi IM, Dobkin LM, Martin JN, Geng EH, Muyindike W, Emenyonu NI, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr. 2009;52(2):280-9.
5. Laurent C. Commentary: HIV testing in low- and middle-income countries: an urgent need for scaling up. J Public Health Policy. 2013;34(1):17-21.
6. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, Lawn SD, et al. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr. 2010;55(3):e17-23.
7. Ochieng-Ooko V, Ochieng D, Sidle JE, Holdsworth M, Wools-Kaloustian K, Siika AM, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88(9):681-8.
8. Mosoko JJ, Akam W, Weidle PJ, Brooks JT, Aweh AJ, Kinge TN, et al. Retention in an antiretroviral therapy programme during an era of decreasing drug cost in Limbe, Cameroon. J Int AIDS Soc. 2011;14:32.
9. Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, Aris E, et al. Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. AIDS. 2011;25(9):1189-97.
10. Somi G, Keogh SC, Todd J, Kilama B, Wringe A, van den Hombergh J, et al. Low mortality risk but high loss to follow-up among patients in the Tanzanian national HIV care and treatment programme. Trop Med Int Health. 2012;17(4):497-506.
11. Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med. 2012;9(9):e1001304.
12. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22(7):873-82. (Pubitemid 351563837)
13. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367(9519):1335-42.
14. Chen SC, Yu JK, Harries AD, Bong CN, Kolola-Dzimadzi R, Tok TS, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health. 2008;13(4):513-9. (Pubitemid 351533602)
15. Maman D, Pujades-Rodriguez M, Subtil F, Pinoges L, McGuire M, Ecochard R, et al. Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa. PLoS One. 2012;7(2):e31078.
16. Boyer S, Eboko F, Camara M, Abe C, Nguini ME, Koulla-Shiro S, et al. Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS. 2010;24(Suppl 1):S5-15.
17. May M, Boulle A, Phiri S, Messou E, Myer L, Wood R, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376(9739):449-57.
18. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, Nelson LJ, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One. 2011;6(4):e18453.
19. Wandeler G, Keiser O, Pfeiffer K, Pestilli S, Fritz C, Labhardt ND, et al. Outcomes of antiretroviral treatment programs in rural Southern Africa. J Acquir Immune Defic Syndr. 2012;59(2):e9-16.
20. Maskew M, Brennan AT, Westreich D, McNamara L, MacPhail AP, Fox MP. Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt). 2013;22(2):113-20.
21. Druyts E, Dybul M, Kanters S, Nachega J, Birungi J, Ford N, et al. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS. 2013;27(3):417-25.
22. DART Virology Group and trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20(10):1391-9.
23. Kipp W, Alibhai A, Saunders LD, Senthilselvan A, Kaler A, Konde-Lule J, et al. Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda. AIDS Care. 2010;22(3):271-8.
24. Muwonga J, Edidi S, Butel C, Vidal N, Monleau M, Okenge A, et al. Resistance to antiretroviral drugs in treated and drug-naive patients in the Democratic Republic of Congo. J Acquir Immune Defic Syndr. 2011;57(Suppl 1):S27-33.
25. Mosha F, Muchunguzi V, Matee M, Sangeda RZ, Vercauteren J, Nsubuga P, et al. Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania. BMC Public Health. 2013;13:38.
26. De Beaudrap P, Thiam M, Diouf A, Toure-Kane C, Ngom-Gueye NF, Vidal N, et al. Risk of virological failure and drug resistance during first and second-line antiretroviral therapy in a 10-year cohort in Senegal: results from the ANRS 1215 cohort. J Acquir Immune Defic Syndr. 2013;62(4):381-7.
27. Fox MP, Cutsem GV, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr. 2012;60(4):428-37.
28. Datay MI, Boulle A, Mant D, Yudkin P. Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;54(5):489-95.
29. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS. 2008;22(16):2117-25.
30. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. 2010 [cited 2013 Feb 7]. Available from: http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf
31. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007;4(2):106-19. (Pubitemid 47248489)
32. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523. (Pubitemid 38263851)
33. Veldkamp AI, Weverling GJ, Lange JMA, Montaner JSG, Reiss P, Cooper DA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15(9):1089-95. (Pubitemid 32549859)
34. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(1):71-5. (Pubitemid 32055781)
35. Bastard M, Fall MB, Laniece I, Taverne B, Desclaux A, Ecochard R, et al. Revisiting long-term adherence to highly active antiretroviral therapy in Senegal using latent class analysis. J Acquir Immune Defic Syndr. 2011;57(1):55-61.
36. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78-84. (Pubitemid 44306492)
37. Roux P, Kouanfack C, Cohen J, Marcellin F, Boyer S, Delaporte E, et al. Adherence to antiretroviral treatment in HIV-positive patients in the Cameroon context: promoting the use of medication reminder methods. J Acquir Immune Defic Syndr. 2011;57(Suppl 1):S40-3.
38. Bila B, Egrot M. Gender asymmetry in healthcare-facility attendance of people living with HIV/AIDS in Burkina Faso. Soc Sci Med. 2009;69(6):854-61.